Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.
Research Interests

Papers共 74 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
169P Outcomes by Comorbidities (cms) with Tremelimumab (T) and Durvalumab (D) in the Phase III HIMALAYA Study in Unresectable Hepatocellular Carcinoma (Uhcc)
L. Rimassa,F. Dayyani,R. K. Kelley, B. Sangro, S. L. Chan, C. L. Mccoy, M. J. Paskow,M. Makowsky, C. Gupta,D. Ran, A. Negro, G. K. Abou-Alfa
ANNALS OF ONCOLOGY (2024): S77-S78
Cited0Views0Bibtex
0
0
167P Non-viral Aetiology Subgroup of the Phase III HIMALAYA Study of Tremelimumab (T) Plus Durvalumab (D) in Unresectable Hepatocellular Carcinoma (Uhcc)
M. E. Reig Monzon, V. C. Tam, B. Sangro, I. Archambeaud,R. K. Kelley, S. L. Chan, M. Kudo, G. Masi, M. J. Paskow,M. Makowsky, C. Gupta,D. Ran, A. Negro, G. K. Abou-Alfa
ANNALS OF ONCOLOGY (2024): S75-S76
Cited0Views0Bibtex
0
0
947MO Five-year Overall Survival (OS) and OS by Tumour Response Measures from the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma (Uhcc)
L. Rimassa, S.L. Chan, B. Sangro, G. Lau, M. Kudo,V. Breder, M. Varela,O. Crysler,M. Bouattour, V.T. Dao, A. Faccio, J. Furuse, L-B. Jeng,Y-K. Kang,R.K. Kelley, M.J. Paskow,M. Makowsky,D. Ran, A. Negro,G.K. Abou-Alfa
Annals of Oncology (2024)
Cited0Views0Bibtex
0
0
Load More
Author Statistics

#Papers: 75

#Citation: 4931

H-Index: 25

G-Index: 53

Sociability: 6

Diversity: 3

Activity: 24

  • 合作者
  • 学生
  • 导师
No result temporarily, you can search similar Scholar with the same research interest
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn